Professional Documents
Culture Documents
COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) Resumen
COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) Resumen
L-Histidine
Vaxzevria is a monovalent vaccine
L-Histidine hydrochloride
composed of a single recombinant,
monohydrate
COVID-19 Vaccine replication-deficient
Children and adolescents Magnesium chloride hexahydrate
(ChAdOx1-S [recombinant]) chimpanzee adenovirus
Vaxzevria is not recommended for Polysorbate 80 (E 433)
/ The Vaxzevria vaccination (ChAdOx1) vector encoding the S The vaccine must not be given:
children aged below 18 years. Ethanol
course consists of two glycoprotein of SARS-CoV-2. The The duration of protection afforded - If you are allergic to the active
Currently there is not enough At the time of analysis, Sucrose https://www.ema.europa.eu/en/medicines/hu
separate doses of 0.5 ml SARS-CoV-2 S immunogen in the by the vaccine is unknown as it is substance or any of the other
information available on the use of 24,244 participants ≥18 years old Sodium chloride
Vaxzevria (previously COVID-19 each. The second dose vaccine is expressed in the If you are pregnant or breastfeeding,
still being determined by ingredients of this vaccine (listed in man/EPAR/vaxzevria-previously-covid-19-
Vaxzevria in children and adolescents had been randomised and received Disodium edetate (dihydrate)
Vaccine AstraZeneca) - Product should be administered trimeric pre-fusion conformation; ongoing clinical trials. Protection - If you have had a blood clot vaccine-astrazeneca
younger than 18 years of think you may be pregnant, or are either Vaxzevria or control. Out of Water for injections /
information at between 4 and 12 weeks (28 the starts from approximately 3 weeks occurring at the same time as having The number of individual cases identified in
age. The safety and efficacy of planning to have a baby, ask your these, 12,282 received at least one One dose (0.5 ml) contains: https://dap.ema.europa.eu/analytics/saw.dll?P
https://www.ema.europa.eu/en/docu to 84 days) after the first coding sequence has not been after the first dose of Vaxzevria. low levels of blood platelets EudraVigilance for COVID-19 VACCINE
Vaxzevria in children and adolescents doctor, pharmacist or nurse for Individuals may not be
dose of Vaxzevria and 10,448 Chimpanzee Adenovirus encoding ortalPages&PortalPath=%2Fshared%2FPHV%20
ments/product-information/vaxzevria- dose - Vaxzevria is for modified in order to stabilise the (thrombosis with thrombocytopenia ASTRAZENECA (CHADOX1 NCOV-19) is
(less than 18 years of age) have not advice before you receive this received two doses. The median the SARS-CoV-2 Spike glycoprotein DAP%2F_portal%2FDAP&Action=Navigate&P0=
previously-covid-19-vaccine- intramuscular injection only, expressed S-protein in the pre- fully protected until 15 days after the syndrome, TTS) after receiving 326,777 (up to 10/07/2021)
yet been established. No data are vaccine. duration of follow-up was 81 days (ChAdOx1-S) 1&P1=eq&P2=%22Line%20Listing%20Objects%2
astrazeneca-epar-product- preferably in the deltoid fusion second dose is administered. As Vaxzevria.
available. - The European Medicines post-dose 2, with 7,158 participants * not less than
information_en.pdf muscle of the upper arm. conformation. Following with all vaccines, vaccination
completing >2 months followup post- 2.5 × 108
- If you have a previous diagnosis of 2.%22Substance%20High%20Level%20Code%22
Agency has deferred the obligation to
Do not inject the vaccine administration, the S glycoprotein with Vaxzevria may not protect all capillary leak syndrome (a condition &P3=1+40995439
submit the results of studies with dose 2 infectious units (Inf.U)
intravascularly, of SARS-CoV-2 is expressed vaccine recipients causing fluid leakage
Vaxzevria in one or more subsets of *Produced in genetically modified
subcutaneously or locally from small blood vessels).
the paediatric population in prevention human embryonic kidney (HEK) 293
intradermally stimulating neutralising antibody
of COVID-19 cells and by recombinant
and cellular immune responses,
DNA technology.
which may contribute to protection
This product contains genetically
to COVID-19.
modified organisms (GMOs).